Acumen Pharmaceuticals, Inc. (ABOS) Current Ratio
- Current ratio · latest quarter: Value 2.47×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.47× | Current assets / current liabilities. $115.51M ÷ $46.85M ≈ 2.47× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 115.51M USD | Assets, Current |
| Current obligations | 46.85M USD | Liabilities, Current |
| Cash and equivalents | 59.44M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 50.75M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 13.38M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $115.51M | $46.85M | $59.44M | $50.75M | (m) | (m) | $13.38M | (m) | 2.47× |
| 2026-03-31 | $133.09M | $29.23M | $51.80M | $76.60M | (m) | (m) | $1.66M | (m) | 4.55× |
| 2025-12-31 | $122.25M | $30.01M | $53.99M | $62.88M | (m) | (m) | $554.00K | (m) | 4.07× |
| 2025-09-30 | $132.15M | $21.96M | $46.83M | $79.78M | (m) | (m) | $682.00K | (m) | 6.02× |
| 2025-06-30 | $148.40M | $24.86M | $36.81M | $106.56M | (m) | (m) | $2.10M | (m) | 5.97× |
| 2025-03-31 | $154.95M | $19.32M | $30.16M | $118.99M | (m) | (m) | $1.06M | (m) | 8.02× |
| 2024-12-31 | $178.31M | $27.61M | $35.63M | $135.93M | (m) | (m) | $5.65M | (m) | 6.46× |
| 2024-09-30 | $207.63M | $19.91M | $33.18M | $167.16M | (m) | (m) | $2.34M | (m) | 10.43× |
| 2024-06-30 | $266.92M | $15.37M | $67.95M | $192.52M | (m) | (m) | $4.21M | (m) | 17.37× |
| 2024-03-31 | $255.83M | $8.47M | $46.93M | $205.58M | (m) | (m) | $3.08M | (m) | 30.20× |
| 2023-12-31 | $246.62M | $12.97M | $66.89M | $176.64M | (m) | (m) | $1.38M | (m) | 19.01× |
| 2023-09-30 | $218.60M | $6.10M | $94.92M | $120.52M | (m) | (m) | $1.36M | (m) | 35.85× |
| 2023-06-30 | $149.54M | $8.53M | (m) | $67.63M | (m) | (m) | $2.03M | (m) | 17.53× |
| 2023-03-31 | $144.03M | $8.78M | (m) | $62.41M | (m) | (m) | $762.00K | (m) | 16.41× |
| 2022-12-31 | $180.33M | $7.81M | $130.10M | $47.50M | (m) | (m) | $1.64M | (m) | 23.08× |
| 2022-09-30 | $202.56M | $6.61M | $157.54M | $42.65M | (m) | (m) | $2.08M | (m) | 30.63× |
| 2022-06-30 | $191.05M | $5.13M | $111.07M | $78.84M | (m) | (m) | $1.71M | (m) | 37.21× |
| 2022-03-31 | $192.10M | $3.94M | $108.76M | $80.33M | (m) | (m) | $1.22M | (m) | 48.81× |
| 2021-12-31 | $198.66M | $5.15M | (m) | $72.08M | (m) | (m) | $1.09M | (m) | 38.60× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |